SEC Form 4 · accession 0001209191-17-053533
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd Erik Zavodnick
Officer — Chief Commercial Officer
Period of report
Sep 18, 2017
Accepted (ET)
Sep 20, 2017 · 8:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 18, 2017 | A | 95,000 | $0.00 | A | 95,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $24.40 | Sep 18, 2017 | A | 35,000 | A | — | Sep 17, 2027 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1Represents a restricted stock award (the "RSA"). The shares underlying the RSA shall vest over a period of four years commencing October 15, 2017, with 25% vesting each year on the annual anniversary of the vesting commencement date, subject to Mr. Zavodnick's Continuous Service (as defined in the Issuer's Amended and Restated 2014 Inducement Plan (the "Plan")) through each such vesting date.
- F2The shares subject to the stock option shall vest over a period of four years commencing September 18, 2017, with 25% vesting on the annual anniversary of the vesting commencement date and 1/48th vesting each month thereafter over the remaining three years, subject to Mr. Zavodnick's Continuous Service (as defined in the Plan) through each such vesting date.